Subscribe
img_2709
26 November 2019Big PharmaTom Phillips

LSPN Europe: understand our business models, say in-house lawyers

The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.

More on this story

Biotechnology
LSPN Europe: AIs should be named inventors, argues Dabus professor
21 November 2019   The team leader behind the world’s first artificial intelligence-generated patent application has said AI inventors will force major changes to the patent system.
Generics
LSPN Europe: new challenges for drug patent owners in Russia
21 November 2019   Russian drug patent owners are being forced to come up with novel solutions to combat generic manufacturers trying to clear the way for competitor medicines.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York